Omeicos Therapeutics, a Berlin, Germany-based biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular diseases, secured an extension of a Series B financing round.
The financial details of the investment were not disclosed.
The round was led by US-based Remiges Ventures, which joined the existing investor consortium including Vesalius Biocapital II S.A. SICAR, a SMS Group company, VC Fonds Technologie Berlin, Hightech Gründerfonds II GmbH & Co. KG (HTGF) and KfW Group. In conjunction with the funding, Taro Inaba, Founder and Managing Partner at Remiges Ventures, will join the Board at Omeicos.
The company intends to use the funds to expand its development efforts for its technology into the field of ophthalmological disorders (like age-related macular degeneration). In conjunction with the round extension, Omeicos established an US-based subsidiary, Omeicos Ophthalmics, in Cambridge, Massachusetts.
Led by Robert Fischer, Dr. med., CSO and co-founder, Omeicos is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection.
Omeicos’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts.